@olsonplanner@RONALDRIBBONS They decide to pay a delivery driver less per package, and therefore they load up more packages even if it means their route runs behind. The package gets no say if the customer doesn’t pay the premium for priority shipping. Sad result is that patients end up waiting.
@olsonplanner@RONALDRIBBONS The thing people don’t understand about the American healthcare system is that patients aren’t the client. Those are the insurance companies. Patients (and their treatments) are the product. The pressure is to produce more, even if it compromises the product.
@DavidAltschulMD Like the BMS to maintain access over the wire, but tricky to size appropriately unless you get good angio of nominal vessel size. Is it drug eluting?
Barnes-Jewish St. Peters Hospital is now a certified Advanced Thrombectomy Capable Stroke Center! This would not have been possible without the tremendous effort of everyone on our team. Thank you and congratulations!
🚨Day 3 kicks off with the SVIN/WFITN joint session! @TudorGJovin discusses the results of In Extremis Laste
📍ASPECTS 0-2 vs 3-5- no heterogeneity of treatment effect
📍size of core is NOT a treatment effect modifier
📍don’t exclude patients from treatment based on core size
Debates: @CheesemakerMD argues against MT in LVO with low NIHSS
✅higher rates of lysis pre MY (?40%)
✅occlusions by definition less eloquent
🛑ICAD much more frequent here, up to 1/3rd = more aggressive maneuvers
🛑3-4x risk of sICH
@svinsociety@YoungNIR@rwregen@SNISinfo
Counterpoint: @hariskamalmd advocates for medical management of asymptomatic carotid stenosis.
- current risk of asymptomatic stenosis can be <1%/yr
- stenosis is dynamic and can even reduce with resolving thrombus or statin use
- need data
@svinsociety#SVIN2023@CREST2_Study
Point: @DanielVelaMD discussing how out of date and simplistic NASCET is on modern treatment paradigms for asymptomatic carotid stenosis.
- lessons in stenting mean probable safer treatments
- other high risk features (inteaplaque hemorrhage/ulceration) ignored
I’ve been light on Twitter (or “X”) since many of the changes this year but had to hop back on to share the excitement of #SVIN23! @svinsociety@YoungNIR
In today’s #GrandRounds, @UHhospitals' Amrou Sarraj, MD (@amrsarrajMD), discussed levels of evidence for thrombectomy (EVT) and the results of the @SELECT2Trial and how EVT of strokes with a large ischemic core is safe and efficacious.
https://t.co/tJbXWvqI2N
It was my pleasure to deliver the key note address @WashUNeurology annual brain attack symposium and grand rounds for the department of Neurology. Thank you @NeuroIntervener for the wonderful hospitality. @JOsbunMDxCV@JinMooLee1